Edwards Lifesciences Corp (EW) concluded trading on Wednesday at a closing price of $75.82, with 9.35 million shares of worth about $709.14 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 15.69% during that period and on February 12, 2025 the price saw a gain of about 6.92%. Currently the company’s common shares owned by public are about 589.80M shares, out of which, 576.38M shares are available for trading.
Stock saw a price change of 5.16% in past 5 days and over the past one month there was a price change of 6.65%. Year-to-date (YTD), EW shares are showing a performance of 2.42% which decreased to -10.81% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $58.93 but also hit the highest price of $96.12 during that period. The average intraday trading volume for Edwards Lifesciences Corp shares is 4.78 million. The stock is currently trading 6.83% above its 20-day simple moving average (SMA20), while that difference is up 4.78% for SMA50 and it goes to 1.12% higher than SMA200.
Edwards Lifesciences Corp (NYSE: EW) currently have 589.80M outstanding shares and institutions hold larger chunk of about 86.65% of that.
The stock has a current market capitalization of $44.72B and its 3Y-monthly beta is at 1.13. PE ratio of stock for trailing 12 months is 10.87, while it has posted earnings per share of $6.97 in the same period. Its PEG reads 1.33 and has Quick Ratio of 2.89 while making debt-to-equity ratio of 0.06. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for EW, volatility over the week remained 1.85% while standing at 2.05% over the month.
Stock’s fiscal year EPS is expected to rise by 0.70% while it is estimated to increase by 11.80% in next year. EPS is likely to shrink at an annualized rate of 8.17% for next 5-years, compared to annual growth of 33.49% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Stifel on January 30, 2025 offering a Buy rating for the stock and assigned a target price range of between $75 and $90 to it. Coverage by Wolfe Research stated Edwards Lifesciences Corp (EW) stock as an Underperform in their note to investors on January 16, 2025, suggesting a price target of $60 for the stock. On December 16, 2024, BofA Securities Upgrade their recommendations, while on October 11, 2024, Morgan Stanley Resumed their ratings for the stock with a price target of $70. Stock get a Hold rating from Jefferies on September 18, 2024.
